Chronic (Cold) Contact Urticaria Treated Successfully with Anti-IgE (Omalizumab)

被引：0
作者：
Ozdemir, Oner [1 ]
机构：
[1] Sakarya Univ, Med Fac, Dept Pediat, Div Pediat Allergy & Immunol, Sakarya, Turkey
来源：
ASTIM ALLERJI IMMUNOLOJI | 2020年 / 18卷 / 01期
关键词：
Urticaria; cold urticaria; inducible urticaria; physical urticaria; omalizumab;
D O I：
10.21911/aai.455
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [31] Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma
    Bousquet, J
    Wenzel, S
    Holgate, S
    Lumry, W
    Freeman, P
    Fox, H
    [J]. CHEST, 2004, 125 (04) : 1378 - 1386
  • [32] Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody
    D'Amato, G
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (02) : 371 - 376
  • [33] Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab
    Picado, C.
    Mascaro Jr, J. M.
    Vlagea, A.
    Pascal, M.
    Munoz-Cano, R.
    Bartra, J.
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2022, 32 (06) : 504 - 506
  • [34] IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
    Maronese, Carlo Alberto
    Ferrucci, Silvia Mariel
    Moltrasio, Chiara
    Lorini, Maurizio
    Carbonelli, Vincenzo
    Asero, Riccardo
    Marzano, Angelo Valerio
    Cugno, Massimo
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [35] Anti-IgE - Omalizumab as an important and permanent therapy option for severe peanut allergy
    Bannert, C.
    Gaupmann, R.
    Schmidthaler, K.
    Gona-Hopler, M.
    Gruber, S.
    Eiwegger, T.
    Dehlink, E.
    Bangert, C.
    Szepfalusi, Z.
    [J]. ALLERGOLOGIE, 2021, 44 (07) : 542 - 547
  • [36] Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria
    Song, Xiaoting
    Liu, Bo
    Yu, Miao
    Liao, Shuanglu
    Luan, Tingting
    Li, Changling
    Zhao, Zuotao
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (02) : 199 - 201
  • [37] The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
    Solèr, M
    Matz, J
    Townley, R
    Buhl, R
    O'Brien, J
    Fox, H
    Thirlwell, J
    Gupta, N
    Della Cioppa, G
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (02) : 254 - 261
  • [38] Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody
    Deniz, VM
    Gupta, N
    [J]. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 29 (01) : 31 - 48
  • [39] Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti-IgE antibody
    Yamo M. Deniz
    Niroo Gupta
    [J]. Clinical Reviews in Allergy & Immunology, 2005, 29 (1) : 31 - 48
  • [40] Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
    Pelaia, Girolamo
    Vatrella, Alessandro
    Busceti, Maria Teresa
    Gallelli, Luca
    Terracciano, Rosa
    Maselli, Rosario
    [J]. CURRENT DRUG TARGETS, 2015, 16 (02) : 171 - 178
12345